Published: 25 February 2022
Author(s): Paula Jiménez-Fonseca, Enrique Gallardo, Fernando Arranz Arija, Jesús Manuel Blanco, Ana Callejo, Diego Cacho Lavin, Marinha Costa Rivas, Joaquín Mosquera, Alberto Rodrigo, Raúl Sánchez Morillas, María Vares Gonzaléz, Andrés Muñoz, Alberto Carmona-Bayonas
Issue: June 2022
Section: Original article

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality among cancer patients. They develop more VTE than those without cancer and experience higher rates of VTE recurrence and haemorrhagic complications [1] that vary depending on patient-related risk factors, tumour site, cancer stage, and anticancer treatments [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.